Literature DB >> 10869395

Role of the beta(3)-adrenoceptor in urine storage in the rat: comparison between the selective beta(3)-adrenoceptor agonist, CL316, 243, and various smooth muscle relaxants.

H Takeda1, Y Yamazaki, M Akahane, Y Igawa, Y Ajisawa, O Nishizawa.   

Abstract

The objective of this study was to compare the effects of a beta(3)-adrenoceptor (beta(3)-AR) agonist on bladder function and cardiovascular parameters in rats with those of several drugs that act on smooth muscle. CL316,243 (beta(3)-AR agonist), isoproterenol (nonselective beta-AR agonist), procaterol (beta(2)-AR agonist), verapamil (Ca(2+) antagonist), and papaverine (antispastic drug) each evoked a concentration-dependent relaxation of the detrusor in vitro. They also reduced bladder pressure in anesthetized rats, the beta-AR agonists apparently being more potent than the other drugs. Atropine (muscarinic antagonist) neither relaxed detrusor strips nor reduced bladder pressure. In anesthetized rats, CL316,243 and atropine each had only a slight influence on blood pressure and heart rate, but isoproterenol, procaterol, verapamil, and papaverine significantly affected cardiovascular function at the same dose range as that required to reduce bladder pressure. In cystometry experiments, CL316,243 (10 microg/kg i.v.), verapamil (1 mg/kg i.v.), and papaverine (1 mg/kg i.v.) all significantly prolonged micturition interval and increased bladder capacity, but did not change the residual urine volume after a micturition contraction. Procaterol (100 microg/kg i.v.) prolonged the micturition interval and increased both bladder capacity and residual urine volume (all significantly). Atropine (100 microg/kg i.v.) reduced micturition pressure and increased residual urine volume (both significantly). Because the human detrusor, like the rat detrusor, relaxes on beta(3)-AR stimulation, we conclude that this beta(3)-AR agonist may have potential in pollakiuria (frequent urination) as a therapeutic agent without cardiovascular side effects.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10869395

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  19 in total

1.  Urothelial beta-3 adrenergic receptors in the rat bladder.

Authors:  F Aura Kullmann; Thomas R Downs; Debra E Artim; Brian J Limberg; Mansi Shah; Dan Contract; William C de Groat; Jan S Rosenbaum
Journal:  Neurourol Urodyn       Date:  2011-01       Impact factor: 2.696

2.  Mirabegron: a review of recent data and its prospects in the management of overactive bladder.

Authors:  Emilio Sacco; Riccardo Bientinesi
Journal:  Ther Adv Urol       Date:  2012-12

Review 3.  Neural control of lower urinary tract and targets for pharmacological therapy.

Authors:  Maria Augusta T Bortolini; Andreisa P M Bilhar; Rodrigo A Castro
Journal:  Int Urogynecol J       Date:  2014-07-08       Impact factor: 2.894

Review 4.  Tools to study beta3-adrenoceptors.

Authors:  Wim Vrydag; Martin C Michel
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2007-01-09       Impact factor: 3.000

5.  Does hypercholesterolemia affect the relaxation of the detrusor smooth muscle in rats? In vitro and in vivo studies.

Authors:  Sibel Bayrak; Zeynep Dicle Balkanci; Bilge Pehlivanoğlu; İsmail Karabulut; Serkan Karaismailoğlu; Ayşen Erdem
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2014-10-26       Impact factor: 3.000

6.  A functional analysis of the influence of β3-adrenoceptors on the rat micturition cycle.

Authors:  Prajni Sadananda; Marcus J Drake; Julian F R Paton; Anthony E Pickering
Journal:  J Pharmacol Exp Ther       Date:  2013-09-05       Impact factor: 4.030

7.  Bladder selectivity of the novel β₃-agonist ritobegron (KUC-7483) explored by in vitro and in vivo studies in the rat.

Authors:  Itaru Maruyama; Yoshiaki Goi; Satoshi Tatemichi; Kazuyasu Maruyama; Yuji Hoyano; Yoshinobu Yamazaki; Hiroshi Kusama
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2012-05-03       Impact factor: 3.000

Review 8.  Use of mirabegron in treating overactive bladder.

Authors:  Alka A Bhide; G Alessandro Digesu; Ruwan Fernando; Vik Khullar
Journal:  Int Urogynecol J       Date:  2012-03-13       Impact factor: 2.894

9.  Effect of mirabegron, a novel β3-adrenoceptor agonist, on bladder function during storage phase in rats.

Authors:  Toshiki Hatanaka; Masashi Ukai; Mai Watanabe; Akiyoshi Someya; Akiyoshi Ohtake; Masanori Suzuki; Koji Ueshima; Shuichi Sato; Seiji Kaku
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2012-12-09       Impact factor: 3.000

10.  Beta-adrenoceptor agonists stimulate endothelial nitric oxide synthase in rat urinary bladder urothelial cells.

Authors:  Lori A Birder; Michele L Nealen; Susanna Kiss; William C de Groat; Michael J Caterina; Edward Wang; Gerard Apodaca; Anthony J Kanai
Journal:  J Neurosci       Date:  2002-09-15       Impact factor: 6.167

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.